A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Summary

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced/Metastatic Solid Tumors
• Bladder Cancer
• Urothelial Carcinoma
• Advanced Non-Small Cell Lung Cancer
• Carcinoma, Non Small Cell Lung
• Carcinoma, Squamous Cell of Head and Neck
• Head and Neck Cancer
• Esophageal Cancer
• Gastroesophageal Junction Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Esophageal Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites